Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma

This study has been completed.
Information provided by:
Eli Lilly and Company Identifier:
First received: November 8, 2005
Last updated: November 5, 2007
Last verified: November 2007

November 8, 2005
November 5, 2007
October 2005
Not Provided
To determine the recommended dose of LY231514 and cisplatin combination therapy, Response Rate
Same as current
Complete list of historical versions of study NCT00251550 on Archive Site
  • Duration of response
  • Progression free survival
  • Median survival time
  • 1 year survival rate
  • Pulmonary function
  • QOL
  • Safety
  • Plasma concentration
Same as current
Not Provided
Not Provided
Study of Pemetrexed Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
Phase I/II Study of LY231514 Plus Cisplatin in Patients With Malignant Pleural Mesothelioma
To investigate efficacy and safety of pemetrexed combined with cisplatin for chemo-naive patients with Malignant Pleural Mesothelioma.
Not Provided
Phase 1
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Malignant Pleural Mesotherioma
  • Drug: Pemetrexed
  • Drug: Cisplatin
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
August 2006
Not Provided

Inclusion Criteria:

  • Inapplicable for radical operation
  • Not received prior systemic chemotherapy
  • Performance status: 0-1

Exclusion Criteria:

  • Having a history of sensitivity to platinum agent, folic acid or vitamin B12
20 Years to 75 Years   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
5249, H3E-JE-ME01
Not Provided
Not Provided
Not Provided
Not Provided
Eli Lilly and Company
Not Provided
Study Director: Call 1-877-CTLILLY(1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time(UTC/GMT - 5 hours, EST) Eli Lilly and Company
Eli Lilly and Company
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP